Monday, April 13, 2009
MONDAY, April 13 (HealthDay News) -- Two compounds are effective in treating advanced prostate cancer resistant to first-line treatments, according to research published online April 9 in Science.
Chris Tran, from Memorial Sloan-Kettering Cancer Center in New York City, and colleagues screened for non-steroidal anti-androgens that bound to androgen receptors with high sensitivity and specificity, particularly in cells expressing high levels of androgen receptor, a hallmark of castration-resistant prostate cancer.
The researchers identified the diarylthiohydantoins RD162 and MDV3100, which had a higher affinity for androgen receptors than the clinically used anti-androgen bicalutamide and blocked the downstream effects of the receptor. In mouse models of castration-resistant prostate cancer, both compounds were able to induce tumor regression when given orally. Of 30 men with castration-resistant prostate cancer who had failed first-line anti-androgens, 43 percent of those treated with MDV3100 had declines of more than 50 percent in the levels of prostate-specific antigen, the authors report.
"These compounds thus appear to be promising candidates for treatment of advanced prostate cancer," Tran and colleagues conclude.
Diabetes & Endocrinology
Copyright © 2009 ScoutNews, LLC. All rights reserved.